-
公开(公告)号：US11760990B2
公开(公告)日：2023-09-19
申请号：US16934397
申请日：2020-07-21
Applicant: Trustees of Boston College
Inventor： Abhishek Chatterjee , James Italia
CPC classification number: C12N9/93 , C12P21/00 , C12Y601/01002
Abstract: Methods and compositions are described for selecting and identifying orthogonal aminoacyl synthetase-tRNA pairs and their use to incorporate unnatural amino acids in a site-specific manner in proteins. Specifically described is a novel E. coli tryptophanyl synthetase-tRNA pair that functions as both an opal and amber suppressor and that incorporates tryptophan analogs into proteins.
-
公开(公告)号：US07528106B2
公开(公告)日：2009-05-05
申请号：US11145587
申请日：2005-06-06
Applicant: Martin Friedlander , Hilda Edith Aguilar , Michael I. Dorrell
Inventor： Martin Friedlander , Hilda Edith Aguilar , Michael I. Dorrell
IPC: A61K38/00 , A61K31/7088 , C07K14/00 , C07H21/00 , A61K31/535
CPC classification number: A61K31/7072 , A61K9/0048 , A61K31/538 , A61K38/00 , A61K45/06 , C12N9/93 , C12Y601/01002 , A61K2300/00
Abstract: The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.
Abstract translation: 本发明提供了通过对患有新生血管疾病或肿瘤的患者施用血管生成抑制药物的组合的血管生成抑制药物的组合物和方法，例如视网膜新生血管疾病和肿瘤，所述血管生成抑制药物包含血管生成抑制性片段 的色氨酰-tRNA合成酶（TrpRS）和至少一种选自血管内皮生长因子（VEGF）信号传导抑制剂和整联蛋白信号传导抑制剂的化合物。 用于该方法的组合物包括色氨酰-tRNA合成酶（TrpRS）的血管生成抑制片段和血管内皮生长因子（VEGF）信号传导抑制剂和整联蛋白信号传导抑制剂中的至少一种与药学上可接受的赋形剂的混合物。
-
3.发明申请Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis 有权可用于调节血管发生的色氨酰-tRNA合成酶衍生的多肽公开(公告)号：US20070218527A1
公开(公告)日：2007-09-20
申请号：US11803326
申请日：2007-05-14
Applicant: Paul Schimmel , Keisuke Wakasugi , Martin Friedlander
Inventor： Paul Schimmel , Keisuke Wakasugi , Martin Friedlander
CPC classification number: C12N9/93 , A61K38/00 , C07H21/04 , C07K14/515 , C07K14/521 , C12Y601/01002 , Y10S435/975
Abstract: The invention provides an isolated nucleic acid encoding a water-soluble polypeptide fragment of human tryptophanyl-tRNA synthetase, which is useful for the inhibition of angiogenesis. The nucleic acid comprises a polynucleotide of SEQ ID NO: 6, a polynucleotide hybridizable to SEQ ID NO: 6, a polynucleotide that encodes the polypeptide of SEQ ID NO: 7, a polynucleotide that encodes a polypeptide of SEQ ID NO: 12, a polynucleotide that encodes a polypeptide epitope of SEQ ID NO: 7, or a polynucleotide that is hybridizable to a polynucleotide that encodes a polypeptide epitope of SEQ ID NO: 7. Vectors and recombinant cells comprising the nucleic acid are also provided.
Abstract translation: 本发明提供编码人色氨酰-tRNA合成酶的水溶性多肽片段的分离的核酸，其可用于抑制血管发生。 核酸包含SEQ ID NO：6的多核苷酸，可与SEQ ID NO：6杂交的多核苷酸，编码SEQ ID NO：7的多肽的多核苷酸，编码SEQ ID NO：12的多肽的多核苷酸， 编码SEQ ID NO：7的多肽表位的多核苷酸或可与编码SEQ ID NO：7的多肽表位的多核苷酸杂交的多核苷酸。还提供了载体和包含该核酸的重组细胞。
-
公开(公告)号：US20170022503A1
公开(公告)日：2017-01-26
申请号：US15124916
申请日：2015-03-13
Inventor： Stuart A. Cook
IPC: C12N15/113 , G01N33/573 , C12Q1/68 , A61K31/422
CPC classification number: C12N15/1137 , A61K31/422 , A61K38/53 , C12N2310/14 , C12N2310/3233 , C12N2320/30 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Y601/01002 , G01N33/5079 , G01N33/573 , G01N33/57484 , G01N2333/9015 , G01N2500/10 , G01N2800/52
Abstract: The present invention provides methods and agents for modulating WARS2 expression, WARS2 activity, or a combination thereof, thereby modulating angiogenesis. Also provided herein are methods for identifying individuals who could benefit from agents that modulate WARS2 expression, WARS2 activity, or a combination thereof.
Abstract translation: 本发明提供用于调节WARS2表达，WARS2活性或其组合的方法和试剂，从而调节血管发生。 本文还提供了用于鉴定可以从调节WARS2表达，WARS2活性或其组合的试剂中受益的个体的方法。
-
5.发明申请Monomeric Forms of Human Aminoacyl-tRNA Synthetases Having Non-Canonical Biological Activities 审中-公开具有非规范生物活性的人类氨基酰基-tRNA合成酶的单体形式公开(公告)号：US20150132277A1
公开(公告)日：2015-05-14
申请号：US14479637
申请日：2014-10-09
Applicant: THE SCRIPPS RESEARCH INSTITUTE
Inventor： Paul Schimmel , Xiang-Lei Yang , Bonnie Slike
CPC classification number: C12N9/93 , A61K38/45 , C07K16/1045 , C07K16/40 , C12Y601/01 , C12Y601/01001 , C12Y601/01002 , C12Y601/01006 , Y02A50/473
Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US20060003933A1
公开(公告)日：2006-01-05
申请号：US11145587
申请日：2005-06-06
Applicant: Martin Friedlander , Hilda Aguilar , Michael Dorrell
Inventor： Martin Friedlander , Hilda Aguilar , Michael Dorrell
IPC: A61K38/47 , A61K31/7072 , A61K31/538
CPC classification number: A61K31/7072 , A61K9/0048 , A61K31/538 , A61K38/00 , A61K45/06 , C12N9/93 , C12Y601/01002 , A61K2300/00
Abstract: The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.
-
7.发明申请公开(公告)号：US20030017564A1
公开(公告)日：2003-01-23
申请号：US10080839
申请日：2002-02-22
Inventor： Paul Schimmel , Keisuke Wakasugi , Martin Friedlander
IPC: C12N009/99 , C12P021/02 , C12N005/06 , C07H021/04
CPC classification number: C12N9/93 , A61K38/00 , C12Y601/01002
Abstract: An isolated, water-soluble polypeptide derived from tryptophanyl-tRNA synthetase is useful for the inhibition of angiogenesis. The polypeptide consists essentially of the amino acid residue sequence 1 SAKGIDYDKL IVRFGSSKID KELINRIERA(SEQ ID NO:12) TGQRPHHFLR RGIFFSHRDM NQVLDAYENK KPFYLYTGRG PSSEAMHVGH LIPFIFTKWL QDVFNVPLVI QMTDDEKYLW KDLTLDQAYG DAVENAKDII ACGFDINKTF IFSDLDYMGM SSGFYKNVVK IQKHVTFNQV KGIFGFTDSD CIGKISFPAI QAAPSFSNSF PQIFRDRTDI QCLIPCAIDQ DPYFRMTRDV APRIGYPKPA LLHSTFFPAL QGAQTKMSAS DPNSSIFLTD TAKQIKTKVN KHAFSGGRDT IEEHRQFGGN CDVDVSFMYL TFFLEDDDKL EQIRKDYTSG AMLTGELKKA LIEVLQPLIA EHQARRKEVT DEIVKEFMTP RKLSFDFQ or an angiogenesis inhibiting fragment thereof. The isolated polypeptide has a size of no more than about 45 kilodaltons. Methods of use of the polypeptide are also provided.
-
公开(公告)号：US09688978B2
公开(公告)日：2017-06-27
申请号：US14368759
申请日：2012-12-27
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Ryan Andrew Adams , Jeffrey D. Watkins , John D. Mendlein
CPC classification number: C12N9/93 , A61K38/00 , C07K16/00 , C07K2319/02 , C07K2319/21 , C07K2319/30 , C07K2319/50 , C12Y601/01002 , C12Y601/01012 , Y02A50/385 , Y02A50/389 , Y02A50/463
Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
-
公开(公告)号：US20140335087A1
公开(公告)日：2014-11-13
申请号：US14368759
申请日：2012-12-27
Applicant: aTyr Pharma, Inc.
Inventor： Ying Ji Buechler , Chi-Fang Wu , Ryan Andrew Adams , Jeffrey D. Watkins , John D. Mendlein
CPC classification number: C12N9/93 , A61K38/00 , C07K16/00 , C07K2319/02 , C07K2319/21 , C07K2319/30 , C07K2319/50 , C12Y601/01002 , C12Y601/01012 , Y02A50/385 , Y02A50/389 , Y02A50/463
Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
Abstract translation: 本发明提供天冬氨酰-tRNA合成酶和Fc区缀合多肽（DRS-Fc缀合物），例如DRS-Fc融合蛋白，包含其的组合物，以及使用这种缀合物和组合物治疗或诊断各种病症的方法。 本发明的DRS-Fc缀合物相对于相应的未修饰的DRS多肽具有改善的控制释放性质，稳定性，半衰期和其它药代动力学和生物学性质。
-
10.发明授权Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities 有权具有非规范生物活性的人氨酰-tRNA合成酶的单体形式公开(公告)号：US08828685B2
公开(公告)日：2014-09-09
申请号：US13577090
申请日：2011-02-04
Applicant: Paul Schimmel , Xiang-Lei Yang , Bonnie Slike
Inventor： Paul Schimmel , Xiang-Lei Yang , Bonnie Slike
CPC classification number: C12N9/93 , A61K38/45 , C07K16/1045 , C07K16/40 , C12Y601/01 , C12Y601/01001 , C12Y601/01002 , C12Y601/01006 , Y02A50/473
Abstract: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.042 seconds)
